[Arg14,Lys15]Nociceptin TFA 

[Arg14,Lys15]Nociceptin TFA is a highly potent and selective NOP receptor (ORL1; OP4) agonist, with an EC₅₀ of 1 nM. [Arg14,Lys15]Nociceptin TFA displays high selectivity over opioid receptors, with IC₅₀s of 0.32, 280, >10000 and 1500 nM for NOP, μ, δ and κ receptors, respectively^[1].

[Arg14,Lys15]Nociceptin TFA is about 30-fold more potent than Nociceptin (NC) and produces longer lasting effects^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In in vivo experiments, [Arg14,Lys15]Nociceptin TFA mimics the effects of NC, producing, after intracerebroventricular administration, pronociceptive effects in the tail-withdrawal assay and inhibiting the locomotor activity of the mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2023.18

C₈₄H₁₃₈F₃N₃₁O₂₄

FGGFTGARKSARKRKNQ

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Okada K, Sujaku T, Chuman Y, et al. Highly potent nociceptin analog containing the Arg-Lys triple repeat. Biochem Biophys Res Commun. 2000;278(2):493-498.  [Content Brief]

  [2]. Rizzi D, Rizzi A, Bigoni R, et al. [Arg(14),Lys(15)]nociceptin, a highly potent agonist of the nociceptin/orphanin FQ receptor: in vitro and in vivo studies. J Pharmacol Exp Ther. 2002;300(1):57-63.  [Content Brief]